Tilos Therapeutics, Inc. — Form D
Tilos Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2017-09-21. The offering totals $4.0M, of which $3.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-09-21
- Form: D
- Accession: 0001678508-17-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $4.0M
- Amount sold: $3.0M
- Remaining: $1.0M
- Investors: 3
- Date of first sale: 2017-09-13
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-295149
Issuer
- Name: Tilos Therapeutics, Inc.
- CIK: 0001678508
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: C/O LABCENTRAL, CAMBRIDGE, MA, 02139
- Phone: 508-233-3923
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| John Edwards | Director | Atlanta, GA |
| Barbara Fox | Director | Cambridge, MA |
| Martin Heidecker | Director | Cambridge, MA |
| Roger Kitterman | Director | Boston, MA |
| Julius Knowles | Director | Somerville, MA |
| John Edwards | Executive Officer | Atlanta, GA |
| Barbara Fox | Executive Officer | Cambridge, MA |
Other filings by this issuer (1)
More